Benadryl

Benadryl is a multinational over-the-counter medicine brand used for allergy, itching, cough and cold relief, depending on the country in which it is sold. The brand is not tied to one universal formulation. In the United States and Canada, the best-known Benadryl allergy products contain diphenhydramine, a first-generation antihistamine used for symptoms including sneezing, runny nose, itching, hives and certain cold-related complaints. Diphenhydramine can cause drowsiness, dizziness, dry mouth, blurred vision and confusion, and it can intensify the effects of alcohol and other central-nervous-system depressants. Benadryl is therefore both an allergy brand and a prominent example of the safety and labeling issues associated with sedating antihistamines. In the United Kingdom, the brand has been used for products containing the second-generation antihistamine acrivastine, including Benadryl Allergy Relief and a version combined with pseudoephedrine for nasal congestion. Some United Kingdom products have also used cetirizine. In Australia, New Zealand and India, Benadryl is principally associated with cough liquids or lozenges rather than the diphenhydramine allergy products most familiar to North American consumers. Australian and New Zealand products have included formulations for dry cough, chesty cough and congestion, using ingredients such as guaifenesin, bromhexine or, historically, pholcodine. Indian products have included diphenhydramine-based cough preparations with additional expectorant or soothing ingredients. The brand’s pharmaceutical background derives from diphenhydramine, which was synthesized in the early 1940s by University of Cincinnati chemist George Rieveschl and student Fred Huber during research into muscle relaxants. Parke-Davis subsequently worked with Rieveschl and developed the compound for medical use. The United States Food and Drug Administration approved diphenhydramine for prescription use in 1946 and for over-the-counter sale in 1982. Before 2007, Benadryl was marketed by Pfizer Consumer Healthcare, whose consumer-health lineage included Warner-Lambert. The brand later became part of Johnson & Johnson’s consumer-health operations through McNeil Consumer Healthcare and is now associated with Kenvue following the separation of Johnson & Johnson’s consumer-health business. Benadryl products are sold in oral tablets, capsules, liquids, creams and gels. The topical range includes itch-relief products for temporary relief of itching associated with allergies, hives and some insect bites. Packaging and labeling have been important to the brand because topical diphenhydramine products can be dangerous if swallowed and because different national formulations can create consumer confusion. In 2010, packaging for Benadryl Itch Stopping Gel was changed after reports of accidental ingestion, adding more prominent skin-only warnings and an additional precautionary sticker. Product recalls that year also involved odor concerns and possible manufacturing or specification problems affecting certain children's allergy products. Benadryl has also attracted public-health attention because diphenhydramine is sometimes used as an unapproved sleep aid or misused in excessive quantities. Medical and sleep organizations have cautioned against relying on sedating antihistamines for chronic insomnia, particularly among older adults, because of next-day impairment, falls, anticholinergic effects and other risks. In 2020, reports that teenagers had been hospitalized or had died after taking very high doses of diphenhydramine led to widespread coverage of the so-called “Benadryl challenge.” The United States FDA publicly warned consumers about the dangers of taking excessive doses. Today, Benadryl remains an active, widely distributed consumer-health brand, but its formulation, regulatory status, ownership history and principal use differ substantially across markets.

Benadryl's history is closely connected with diphenhydramine, the first-generation antihistamine used in the brand's principal North American allergy products. Diphenhydramine was synthesized in 1943 by Fred Huber while he was working with George Rieveschl at the University of Cincinnati. The research initially concerned muscle relaxants. Rieveschl subsequently collaborated with Parke-Davis, which tested the compound and licensed the relevant patent. The medicine was approved in the United States for prescription use in 1946 and later became available over the counter in 1982. The Benadryl name developed into a consumer brand rather than a single globally standardized medicine. In the United States and Canada, it became associated mainly with diphenhydramine allergy products, including oral tablets, capsules and children's liquids. These products are used for symptoms such as sneezing, itching, runny nose, hives and some cold-related complaints. Topical creams and gels extended the brand into temporary itch relief. Because diphenhydramine is sedating and has anticholinergic effects, drowsiness, dizziness, dry mouth, blurred vision and confusion are important safety considerations. The ingredient can also interact with alcohol, sedatives, sleep medicines, muscle relaxants, antidepressants and other antihistamines. The brand's ownership and marketing history has passed through several consumer-health organizations. Before 2007, Benadryl was marketed by Pfizer Consumer Healthcare, whose business history included Warner-Lambert. It later became part of Johnson & Johnson's consumer-health portfolio and was marketed through McNeil Consumer Healthcare. After Johnson & Johnson separated its consumer-health business, the relevant portfolio became part of Kenvue. Benadryl is therefore best understood as a Kenvue brand today, rather than as a product owned directly by Johnson & Johnson, although the latter remains an important part of its corporate history. Outside North America, the brand has developed different identities. United Kingdom Benadryl allergy products have used acrivastine, a less-sedating second-generation antihistamine, and some versions have combined acrivastine with pseudoephedrine for congestion. In Australia, New Zealand and India, Benadryl has commonly appeared as a cough medicine. Formulations in those markets have included combinations involving diphenhydramine, dextromethorphan, guaifenesin, bromhexine, ammonium chloride, citrate or other locally approved ingredients. This variation means that consumers cannot safely infer the active ingredient or intended use from the brand name alone. Quality, packaging and misuse issues have shaped the brand's public profile. In January 2010, McNeil recalled five lots because of an unusual odor associated with 2,4,6-tribromoanisole. Later that year, more than four million packs of Benadryl Children's Allergy tablets were recalled over concerns about ingredient concentration and inactive-ingredient testing. Benadryl Itch Stopping Gel also received packaging changes after reports of accidental oral ingestion, with clearer skin-only labeling and an additional warning sticker. Diphenhydramine's sedative properties have made Benadryl a commonly used, though not generally preferred, over-the-counter sleep aid. Sleep specialists have discouraged routine use of sedating antihistamines for chronic insomnia, citing daytime impairment, grogginess, falls and anticholinergic concerns. In 2020, reports of teenagers taking dangerous quantities of diphenhydramine in connection with a social-media trend led to further media coverage and a public warning from the FDA. Benadryl remains active internationally, but its products, ingredients, indications and safety labeling continue to depend on the market.

• 2020

  Diphenhydramine misuse warnings

  [1]Benadrylen.wikipedia.org

  Reports involving high-dose misuse among teenagers prompted renewed public-health warnings about diphenhydramine.

• 2010

  Recalls and topical-labeling changes

  [1]Benadrylen.wikipedia.org

  Several Benadryl recalls occurred, while topical gel packaging gained stronger warnings against ingestion.

• 2007

  Marketing responsibility changed

  [1]Benadrylen.wikipedia.org

  Benadryl was no longer marketed by Pfizer Consumer Healthcare and subsequently became associated with Johnson & Johnson Consumer Health.

• 1982

  U.S. over-the-counter approval

  [1]Benadrylen.wikipedia.org

  Diphenhydramine became approved for over-the-counter sale in the United States.

• 1946

  U.S. prescription approval

  [1]Benadrylen.wikipedia.org

  Diphenhydramine received U.S. approval for prescription use.

• 1943

  Diphenhydramine synthesized

  [1]Benadrylen.wikipedia.org

  Fred Huber synthesized diphenhydramine during University of Cincinnati research conducted with George Rieveschl.

A mass-market, accessible over-the-counter relief brand spanning allergy, itch, cough and cold categories, with formulations adapted to local regulations and consumer needs.

• Oral antihistamine

  Benadryl Allergy

  A United States and Canadian allergy product generally containing diphenhydramine. It is used for temporary relief of symptoms such as sneezing, runny nose, itching, hives and some cold-related complaints. As a first-generation antihistamine, it commonly causes drowsiness and may also cause dizziness, dry mouth, blurred vision or confusion.

• Children's oral antihistamine

  Benadryl Allergy for Children

  A liquid children's allergy formulation sold in North America for symptoms including sneezing, runny nose, itchy eyes and hives. Children's products require careful dose and age guidance because diphenhydramine can cause substantial sedation or, in some children, paradoxical excitation.

• Topical itch relief

  Benadryl Itch Stopping Cream and Gel

  Topical products sold in the United States and Canada for temporary relief of itching associated with allergies, hives and some insect bites. The cream formulation has been described as containing diphenhydramine hydrochloride and zinc acetate. These products are intended for external use and must not be swallowed.

• United Kingdom oral antihistamine

  Benadryl Allergy Relief

  A United Kingdom Benadryl allergy product based on acrivastine rather than the diphenhydramine formulation familiar in North America. It is used for conditions such as hay fever, hives, insect reactions, conjunctivitis and eczema-related allergy symptoms.

• Antihistamine and decongestant

  Benadryl Allergy Relief Plus Decongestant

  A United Kingdom combination product containing acrivastine and pseudoephedrine. It is intended to address allergy symptoms together with nasal congestion, blocked or runny nose and related sinus discomfort.

• Cough and cold medicines

  Benadryl Cough Medicines

  In Australia, New Zealand and India, Benadryl is widely associated with cough liquids and, in India, cough lozenges. Regional products cover dry or tickly coughs, chest congestion and coughs accompanied by nasal symptoms, with ingredients varying by formulation and jurisdiction.

• 2020

  High-dose diphenhydramine misuse and the Benadryl challenge

  Reports of teenagers being hospitalized or dying after taking excessive amounts of diphenhydramine were linked in media coverage to a purported social-media challenge. The reports led to renewed warnings about overdose risks and the dangers of treating the medicine as a recreational product.

  Source

• 2010

  Benadryl lot recalls over odor and quality concerns

  McNeil Consumer Healthcare recalled five lots after an unusual odor was associated with 2,4,6-tribromoanisole. A separate recall affected more than four million packs of children's allergy tablets because of concerns about ingredient concentration and inactive-ingredient testing.

  Source

Read more

• 2020

  Respond to diphenhydramine misuse concernsStrategy

  Background

  Reports of dangerous high-dose use among teenagers generated concern about social-media-driven misuse of a widely available sedating antihistamine.

  Action taken

  Public-health authorities, including the FDA, issued warnings emphasizing the dangers of exceeding labeled doses.

  Aftermath

  The episode reinforced the importance of dose controls, age-appropriate use, caregiver education and clear communication about sedation and overdose risks.

  Source

• 2010

  Strengthen topical-use warningsStrategy

  Background

  Reports described accidental ingestion of Benadryl Itch Stopping Gel, creating a risk that consumers could mistake a topical product for an oral medicine.

  Action taken

  The packaging was redesigned with a clearer skin-only warning and an additional precautionary sticker.

  Aftermath

  The change made route-of-administration information more prominent and reflected broader attention to medication packaging safety.

  Source

1. 1Benadrylen.wikipedia.org